睿昂基因发布2025年业绩预告，营收预计1.7亿-1.76亿元

Core Viewpoint - Ruiang Gene forecasts an annual revenue of 170 million to 176 million yuan for 2025, indicating a significant decline in profit due to various factors [1] Group 1: Revenue and Profit Decline - The company expects a revenue decrease of approximately 66.31 million to 72.31 million yuan in 2025, representing a year-on-year decline of 27.36% to 29.84% [1] - The decline in revenue has led to a reduction in gross profit [1] Group 2: Factors Contributing to Decline - Increased competition in the in vitro diagnostics industry and specific events affecting the company have negatively impacted revenue [1] - Slower payment collection from downstream clients due to the medical industry environment has resulted in increased provisions for credit impairment losses on accounts receivable [1] - The suspension of the molecular diagnostic reagent R&D center and industrialization project, with no plans for resumption, has led to impairment losses being recognized [1] - Performance declines in subsidiaries Shanghai Yuanqi Bio and Wuhan Baitai have prompted the company to recognize goodwill impairment losses and asset impairment losses, respectively, due to changes in the external market environment [1] Group 3: Tax Asset Adjustments - The significant decline in performance for both the parent and subsidiary companies has led to a reassessment of future taxable income, resulting in the write-off of previously recognized deferred tax assets [1]